Improvements in Acute Liver Failure Outcomes in the U.S.

Reduced liver transplantation and improved survival were observed between 1998 and 2013.

To determine recent trends in causes, treatments, and outcomes of acute liver failure (ALF) in the U.S., researchers conducted an observational cohort study involving 2070 patients with ALF who were consecutively enrolled between 1998 and 2013 from 31 U.S. transplant centers.

Between the periods 1998–2005 and 2006–2013, the following significant changes were noted: decreased listing for (44% to 32%) and receipt of (25% to 20%) liver transplantation at 21 days postenrollment, increased survival (67% to 75%) at 21 days, reduced need for blood (44% to 28%) or plasma (65% to 47%) transfusion within 7 days postenrollment, and decreased use of vasopressors within 7 days (35% to 28%). The distribution of primary cause for ALF remained consistent du…

Reviewing Author

M. Brian Fennerty, MD

Disclosures

Consultant/Advisory boardDSMB for Intec trial; SERES trial; C3 Therapeutics trial

M. Brian Fennerty, MD

Disclosures

Consultant/Advisory boardDSMB for Intec trial; SERES trial; C3 Therapeutics trial

Improvements in Acute Liver Failure Outcomes in the U.S.

Topics

Reviewing Author